Baylor Study Reveals Metformins Brain Mechanism

A new study from researchers at Baylor College of Medicine has revealed that metformin, the widely used first-line treatment for type 2 diabetes, exerts part of its blood sugar-lowering effects directly in the brain, challenging long-held assumptions about the drug's mechanisms. The findings, published in the journal Science Advances, identify a specific brain pathway involving a protein called Rap1 in the ventromedial hypothalamus, a region that regulates metabolism. Conducted primarily on mice, the research suggests this neural action could lead to more targeted diabetes therapies.

For over 60 years, metformin has been prescribed to millions to manage type 2 diabetes by reducing glucose production in the liver, enhancing the body's sensitivity to insulin, and influencing glucose absorption in the gut. Approved for use in humans since the 1950s, the inexpensive oral medication is typically recommended when diet and exercise alone fail to control blood sugar levels. It is also used off-label for conditions like polycystic ovary syndrome to improve insulin resistance and ovulation, though it is not formally licensed for that purpose.

The Baylor team, led by Makoto Fukuda, an...